Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06694636

Enrollment

Registered

2024-11-19

Start date

2024-02-01

Completion date

2026-02-01

Last updated

2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular Carcinoma, Sympathetic Nerves, Intravascular Radiofrequency Ablation

Brief summary

Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.

Interventions

PROCEDUREendovascular radiofrequency ablation and desympathetic nerve surgery

endovascular radiofrequency ablation and desympathetic nerve surgery

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Enrolled patients will receive intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma

Eligibility

Sex/Gender

ALL

Age

25 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Clinically or pathologically confirmed hepatocellular carcinoma (HCC) * Locally progressed or distant metastatic unresectable advanced HCC * Progressed after second-line therapy * Agree to participate in the study and sign the informed consent form

Exclusion criteria

* Not suitable for ablation surgery * Pregnant, lactating and planning to become pregnant * Orthostatic hypotension * Mixed liver cancer * Intestinal obstruction * Obvious bleeding tendencies and hematologic diseases * Acute or severe systemic infection; * Stroke or transient ischemic attack (TIA) within two weeks; * Acute coronary syndrome within two weeks; * Evaluated to be not suitable for this trial by investigators

Design outcomes

Primary

Measure	Time frame	Description
ORR	every month, up to 1 year	Objective Response Rate

Secondary

Measure	Time frame	Description
PFS	every month, up to 1 year	Progression Free Survival
DCR	every month, up to 1 year	disease control rate

Countries

China

Contacts

Primary ContactHai-Dong Zhu

zhuhaidong9509@163.com+86-25-83272121

Backup ContactTeng

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026